Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 6;10(8):990.
doi: 10.3390/pathogens10080990.

Unpredictable In Vitro Killing Activity of Amphotericin B against Four Candida auris Clades

Affiliations

Unpredictable In Vitro Killing Activity of Amphotericin B against Four Candida auris Clades

Zoltán Papp et al. Pathogens. .

Abstract

Candida auris is an emerging multiresistant yeast against which amphotericin B (AMB) is still the first therapeutic choice in certain clinical situations (i.e., meningitis, endophthalmitis, and urinary tract infections). As data about the in vitro killing activity of AMB against C. auris clades are lacking, we determined MICs, minimum fungicidal concentrations (MFCs), and killing activity of AMB against 22 isolates representing the 4 major C. auris clades (South Asian n = 6; East Asian n = 4; South African n = 6, and South American n = 6). MIC values were ≤1 mg/L regardless of clades; MFC ranges were, 1-4 mg/L, 2-4 mg/L, 2 mg/L, and 2-8 mg/L for South Asian, East Asian, South African, and South American clades, respectively. AMB showed concentration-, clade-, and isolate-dependent killing activity. AMB was fungicidal at 1 mg/L against two of six, two of four, three of six, and one of six isolates from the South Asian, East Asian, South African, and South American clades, respectively. Widefield fluorescence microscopy showed cell number decreases at 1 mg/L AMB in cases of the South Asian, East Asian, and South African clades. These data draw attention to the weak killing activity of AMB against C. auris regardless of clades, even when MICs are low (≤1 mg/L). Thus, AMB efficacy is unpredictable in treatment of invasive C. auris infections.

Keywords: Candida auris; amphotericin B; in vitro; killing rate; time–kill.

PubMed Disclaimer

Conflict of interest statement

L. Majoros has received conference travel grants from MSD, Cidara, Astellas and Pfizer.

Figures

Figure 1
Figure 1
Time–kill plots of amphotericin B against Candida auris isolates 174 (A), type strain (NCPF 13029 = CBS 10913) (B), 182 (C), and I-172 (D), belonging to the South Asian, East Asian, South African, and South American clades, respectively.
Figure 2
Figure 2
Killing rate values of amphotericin B against 22 clinical isolates belonging to the South Asian (A), East Asian (B), South African (C), and South American (D) Candida auris clades. Positive and negative k values indicate the decrease and increase, respectively, in viable cell numbers. Error bars are omitted for better visualization of the graphics.
Figure 3
Figure 3
Candida auris cells (isolates 196, South Asian clade and I-156, South American clade) treated with 0.5 and 1 mg/L amphotericin B and examined with widefield fluorescence microscopy. Drug-free controls were included. Micrographs were taken after 24 h. Blue cells indicate viable cells. In the case of isolate 196 (left), cell numbers decreased at 1 mg/L. For isolate I-156 (right), large aggregates with up to 50 cells were seen at 1 mg/L. Dead cells were never detected. Bar: 10 µm.

Similar articles

Cited by

References

    1. Satoh K., Makimura K., Hasumi Y., Nishiyama Y., Uchida K., Yamaguchi Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol. 2009;53:41–44. doi: 10.1111/j.1348-0421.2008.00083.x. - DOI - PubMed
    1. Allaw F., Zahreddine K.N., Ibrahim A., Tannous J., Taleb H., Bizri A.R., Dbaibo G., Kanj S.S. First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon. Pathogens. 2021;10:157. doi: 10.3390/pathogens10020157. - DOI - PMC - PubMed
    1. Sekyere O.J. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. MicrobiologyOpen. 2018;7:e578. doi: 10.1002/mbo3.578. - DOI - PMC - PubMed
    1. Lockhart S.R., Etienne K.A., Vallabhaneni S., Farooqi J., Chowdhary A., Govender N.P., Colombo A.L., Calvo B., Cuomo C.A., Desjardins C.A., et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis. 2017;64:134–140. doi: 10.1093/cid/ciw691. - DOI - PMC - PubMed
    1. Chow N.A., de Groot T., Badali H., Abastabar M., Chiller T.M., Meis J.F. Potential fifth clade of Candida auris, Iran, 2018. Emerg. Infect. Dis. 2019;25:1780–1781. doi: 10.3201/eid2509.190686. - DOI - PMC - PubMed